C12N 2740/12041
Use of virus, viral particle or viral elements as a vector
C12N2740/12041 (Use of virus, viral particle or viral elements as a vector) appears on 10 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 10
- Assignees
- 17
- Inventors
- 37
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/12043Viral genome or elements thereof as genetic vectorIndexing code10
- C12N 2740/12045Special targeting system for viral vectorsIndexing code1
- C12N 2740/12042Virus or viral particle as vehicleIndexing code0
- C12N 2740/12044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Recombinant retroviral vectors for gene therapy25 Aug 2026US 12,716,074 B1United Arab Emirates University
- Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens2 Feb 2016US 9,248,178 B2
- Methods for generation of antibodies8 Oct 2013US 8,551,968 B2National Jewish Health
- Methods and compositions related to high-titer pseudotyped retroviruses27 Oct 2009US 7,608,449 B2The Regents of the University of California
- Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences11 Jul 2006US 7,074,398 B1GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Modular betaretrovirus receptor attachment and cell entry proteins8 May 2025US 2025/0144238 A1
- Engineering of gamma delta t cells and compositions thereof17 Oct 2024US 2024/0344024 A1GammaDelta Therapeutics Ltd
- Nucleic acids encoding human fus protein and use in the treatment of amyotrophic lateral sclerosis (als)25 Jan 2024US 2024/0024513 A1Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Methods for generation of antibodies12 Jun 2014US 2014/0162357 A1National Jewish Health
Most cited
By later US patents
- Methods of enhancing antigen-specific T cell responses55US 5,738,852 ASolis Therapeutics, Inc. · 1998
- Engineered antigen presenting cells and methods for their use42US 5,962,320 ALeland Stanford Junior University · 1999
- Methods for generation of antibodies5US 8,551,968 B2National Jewish Health · 2013
- Method of producing foreign gene products4US 5,646,013 ADaiichi Seiyaku Co., Ltd. · 1997
- Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences2US 7,074,398 B1GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH · 2006